- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03721783
Infant and Child European Cryoablation Project ICECaP
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cryoablation involves image-guided insertion of single-use specialised needles or probes through the skin into a soft tissue or bone lesion. A mechanised unit is connected to the probe(s) and generates cyclical freezing and thawing of the tissues at the probe tip(s) via exchange of highly pressurised gases through the probe lumen(s), utilising the Joules-Thomson effect. Extreme freezing and thawing of the lesion causes permanent tissue destruction through both mechanical disruption of tissue membranes and a secondary immune response effect.
Cryoablation is one of several minimally invasive ablative techniques used to reduce the size of or to eradicate soft tissue and bone lesions. Ablative techniques are now an accepted standard of care for many benign and malignant lesions in adult practice. Cryoablation is widely used in the management of renal cell carcinoma, with medium-term outcomes matching surgical resection.
The advantages of cryoablation over surgery, particularly in a paediatric population, are:
- Minimally invasive approach, therefore suitable for day case procedures and almost scarless
- Significantly faster recovery times compared to complex surgical debulking
- Minimal complication rates compared to surgery (less risk to nerves, blood vessels and critical solid organ)
- Affords excellent pain relief (has an independent role in chronic pain management)
To date the use of cryoablation in children remains novel and under reported.
The purpose of this registry is to audit the current range of applications, technical success rate, safety profile, complication rate and efficacy of cryoablation procedures in children. This registry would, as a minimum, clarify current practice and outcomes within individual centres, allowing teams to audit and benchmark their own procedures and aiming to align practice amongst individual hospitals. A registry would aim to generate a body of evidence to establish parameters for best practice and may highlight conditions that respond better or worse than others to this novel therapy. The audit may lead to a clinical trial for the treatment of one or more specific conditions but in the interim would provide evidence for the efficacy and safety of the procedure and will aim to protect against indiscriminate use of this treatment modality in children in the future.
Registry design: This is a prospective multi-centre, open, non-controlled repeat treatment registry and data collection in collaboration with individual hospitals in the UK and Europe.
The proposal is for a robust, multi-centre data collection system to support and establish the treatment pathway, safety parameters and outcomes of paediatric cryoablation. The number of procedures performed in each centre will be understandably small, given the specialist nature of this emerging modality and the small numbers of patients being offered this treatment. The registry aims to collect standardised data from all centres performing cryoablation in children to allow robust audit of this procedure. Multiple data sets will be collected and entered into an anonymised web based host.
Upon completion of recruitment and follow up, the data will be subject to uni-variate and multi-variate analysis.
The registry is designed with the patient at the centre of the data collection and outcomes. Anonymised data will be analysed collectively but will ultimately be owned and retained by individual trusts. Details of the full data set proposed are detailed in the attached study protocol.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Alex Barnacle, BM
- Phone Number: +447810792517
- Email: Alex.Barnacle@gosh.nhs.uk
Study Contact Backup
- Name: Premal Patel, BM
- Phone Number: +442078297943
- Email: Premal.Patel@gosh.nhs.uk
Study Locations
-
-
-
London, United Kingdom, WC1N 3JH
- Recruiting
- Great
-
Contact:
- Alex Barnacle
- Email: Alex.Barnacle@gosh.nhs.uk
-
Contact:
- Premal Patel
- Email: Premal.Patel@gosh.nhs.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- all children in whom a clinical decision is made to treat with percutaneous cryoablation, to include those in whom cryoablation was not technically or clinically possible at any stage.
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
children with soft tissue lesions
All children who undergo cryoablation therapy for benign soft tissue lesions
|
Image guided cryoablation therapy of soft tissue lesions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence and severity of complications arising from cryoablation treatment
Time Frame: 2 years
|
Documentation and severity scoring of any complications arising from a cryoablation procedure, using the Society of Interventional Radiology (SIR) standards of practice committee classification of complications by outcome scoring system.
The range of the outcome scoring system is A-F, with A being the least severe (no therapy, no consequence), and F being the most severe (resulting death).
[Omary et al.
J Vasc Interv Radiol 2003; 14:S293-S295]
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in maximal diameter of lesion following treatment
Time Frame: 5 years
|
In patients where this is applicable, measure change in maximal lesion diameter on ultrasound or MRI imaging, comparing baseline (pre-treatment) lesion diameter to (post treatment) lesion diameter at 2 years.
Subsequent lesion measurements will be made annually up to 5 years (for patients included in follow up).
|
5 years
|
Change in symptomatology following treatment
Time Frame: 2 years
|
Where applicable, measure change in symptomatology post treatment, as assessed by PedsQL Pediatric Quality of Life Inventory UK questionnaire version 4.0.
This is a scored questionnaire used for the assessment of physical functioning, emotional functioning, social functioning and school functioning.
It is completed by both the child (child report) and the parent (parent report).
Each questionnaire consists of 23 items graded 0-4 where 0 equates to no functional deficit and a maximum achievable score of 92 equates to the most severe functional deficit.
Combined parent and child reports are collated to give a range of scores of 0-184 per assessment.
|
2 years
|
Procedure failure
Time Frame: 3 years
|
This is a composite outcome defined as having the presence of any (or all) of the following: absence of consent, patient not fit for procedure, clinical complication, technical failure of equipment.
This data will be collected over the 3 years of procedure recruitment into the registry.
|
3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Alex Barnacle, BM, Great Ormond Street Hospital, London, UK
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 18BB37
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Therapy
-
University of SevilleCompletedGait | Physical Therapy | Sports Physical Therapy | Exercise TherapySpain
-
Biotronik SE & Co. KGCompletedCardiac Resynchronization Therapy | Pacemaker TherapyGermany, Austria, Spain, Switzerland
-
University of Sao PauloUnknownFrail Elderly | Exercise Therapy | Physical Therapy Techniques
-
Palo Alto Veterans Institute for ResearchCompletedWritten Exposure Therapy | Imaginal Exposure TherapyUnited States
-
University of NebraskaRecruitingPediatric ALL | Child, Hospitalized | Occupational Therapy | Physical Therapy Modalities | Animal Assisted TherapyUnited States
-
Guangzhou Concord Cancer CenterSun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Varian, a Siemens...CompletedSolid Tumor | Proton Therapy | Radiation TherapyChina
-
Medical University of South CarolinaNational Endowment for the Arts, United StatesRecruitingPhysical Therapy | Hematopoietic Stem Cell Transplantation | Art TherapyUnited States
-
Reynolds Army Community HospitalTemple University; Brooke Army Medical CenterUnknownPhysical Therapy Direct Access | Physical Therapy Primary CareUnited States
-
University of Rhode IslandCompletedCognitive Behavior Therapy | Relaxation Therapy | Motivational Intervention | Nicotine AnonymousUnited States
-
SEMRA BÜLBÜLOĞLUCompletedMindfullnes-Based Cognitive Therapy and Adherence to Immunosuppressive TherapyTurkey
Clinical Trials on Cryoablation
-
Boston Scientific CorporationTerminated
-
Boston Scientific CorporationTerminatedPain | Pancreatic CancerUnited States
-
Mayo ClinicRecruitingPrimary Malignant Neoplasm of Prostate (Diagnosis)United States
-
Boston Scientific CorporationCompletedPain | Neoplasm MetastasisUnited States, Canada, France
-
Boston Scientific CorporationCompletedMetastatic Lung CancerUnited States, France
-
afreeze GmbHAccovion GmbHTerminatedPathologic Processes | Heart Diseases | Cardiovascular Diseases | Arrhythmias, Cardiac | Atrial Fibrillation (Paroxysmal)Austria, Germany, Switzerland
-
Boston Scientific CorporationWithdrawn
-
Boston Scientific CorporationCompletedNeoplasm MetastasisUnited States, France
-
Boston Scientific CorporationCompletedPain | Neoplasm Metastasis | Bone Metastasis of Diverse OriginsUnited States, France
-
Shanghai 10th People's HospitalNot yet recruitingHypertension | Paroxysmal Atrial FibrillationChina